← Eichor
Study identifier: NCT06630065 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine

Condition: Depressive Disorder  ·  Sponsor: Centre Hospitalier St Anne

PhaseNA
Planned participants96
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

Major depressive disorder is the leading cause of disability worldwide, affecting up to 300 million people each year, and one in five people will experience depression at least once in their lives. Emotional bias is an essential component of characterized depressive episodes, leading depressed patients to attribute a more negative valence to emotional stimuli. On the basis of recent and robust neuroscientific data revisiting the role of the cerebral amygdala as an essential essential structure for encoding the negative and positive valences and of emotional stimuli, the team has shown in mice that a depressive phenotype induced by a chronic administration of corticosterone, a well-known model of depression, is associated with a change in hedonic value allocation, i.e. pleasant odors become less pleasant, and aversive odors become even more unpleasant, mimicking what happens in humans (identical data in humans). It assumes that: 1. There is a negative emotional bias in depressed patients compared with control subjects, evidenced by the assignment of more negative valences when viewing images. 2. In depressed subjects, compared with controls subjects, there is greater activation of the basolateral amygdala/ventral hippocampus pathway (the level of imaging resolution of imaging does not allow to study the basolateral amygdala/central amygdala pathway in humans) and less of the basolateral amygdala/nucleus accumbens pathway. 3. In depressed subjects, improvement in negative em…

This description comes directly from the study's public registry record.

Talk to the study team

Chantal Henry, Pr  ·  0145658452  ·  ch.henry@ghu-paris.fr

Khaoussou Sylla, Dr  ·  0145657728  ·  k.sylla@ghu-paris.fr

Always discuss trial participation with your own doctor first.

Locations (1)

- Groupe hospitalo-universitaire Paris Psychiatrie et NeurosciencesParis, Paris, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06630065